Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab

K. Muylle; P. Flamen; D. Vugts; T. Guiot; G. Ghanem; N. Meuleman; P. Bourgeois; B. Vanderlinden; G.A.M.S. van Dongen; H. Everaert; M. Vaes; D. Bron

doi:10.1007/s00259-015-3025-6

Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab

K. Muylle, P. Flamen, D. Vugts, T. Guiot, G. Ghanem, N. Meuleman, P. Bourgeois, B. Vanderlinden, G.A.M.S. van Dongen, H. Everaert, M. Vaes, D. Bron

Radiology and nuclear medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1304-1314
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	42
Issue number	8
DOIs	https://doi.org/10.1007/s00259-015-3025-6
Publication status	Published - 2015

Access to Document

10.1007/s00259-015-3025-6

Cite this

Muylle, K., Flamen, P., Vugts, D., Guiot, T., Ghanem, G., Meuleman, N., Bourgeois, P., Vanderlinden, B., van Dongen, G. A. M. S., Everaert, H., Vaes, M., & Bron, D. (2015). Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab. European Journal of Nuclear Medicine and Molecular Imaging, 42(8), 1304-1314. https://doi.org/10.1007/s00259-015-3025-6

@article{570572b536fc4a34a0ffe5ee87e2999b,

title = "Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab",

author = "K. Muylle and P. Flamen and D. Vugts and T. Guiot and G. Ghanem and N. Meuleman and P. Bourgeois and B. Vanderlinden and {van Dongen}, G.A.M.S. and H. Everaert and M. Vaes and D. Bron",

year = "2015",

doi = "10.1007/s00259-015-3025-6",

language = "Undefined/Unknown",

volume = "42",

pages = "1304--1314",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "8",

}

Muylle, K, Flamen, P, Vugts, D, Guiot, T, Ghanem, G, Meuleman, N, Bourgeois, P, Vanderlinden, B, van Dongen, GAMS, Everaert, H, Vaes, M & Bron, D 2015, 'Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab', European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, no. 8, pp. 1304-1314. https://doi.org/10.1007/s00259-015-3025-6

Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab. / Muylle, K.; Flamen, P.; Vugts, D. et al.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, No. 8, 2015, p. 1304-1314.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab

AU - Muylle, K.

AU - Flamen, P.

AU - Vugts, D.

AU - Guiot, T.

AU - Ghanem, G.

AU - Meuleman, N.

AU - Bourgeois, P.

AU - Vanderlinden, B.

AU - van Dongen, G.A.M.S.

AU - Everaert, H.

AU - Vaes, M.

AU - Bron, D.

PY - 2015

Y1 - 2015

U2 - 10.1007/s00259-015-3025-6

DO - 10.1007/s00259-015-3025-6

M3 - Article

C2 - 25792453

VL - 42

SP - 1304

EP - 1314

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 8

ER -

Muylle K, Flamen P, Vugts D, Guiot T, Ghanem G, Meuleman N et al. Tumour targeting and radiation dose of radioimmunotherapy with Y-90-rituximab in CD20+B-cell lymphoma as predicted by Zr-89-rituximab immuno-PET: impact of preloading with unlabelled rituximab. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42(8):1304-1314. doi: 10.1007/s00259-015-3025-6